Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$170.85 USD
+3.44 (2.05%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $170.84 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DGX 170.85 +3.44(2.05%)
Will DGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
Other News for DGX
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene ...
Quest Diagnostics Inc (DGX) Unveils Advanced Genetic Test for Ataxia Using PacBio's PureTarget ...
Quest Diagnostics (DGX) Sees Price Target Reduced by Piper Sandler
Quest Diagnostics price target lowered by $10 at Piper Sandler, here's why
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity